Chain Length Does Matter: Development of High-Potency QS-21-Based Vaccine Adjuvants

Adjuvants are crucial agents that enhance the immunogenicity
of
vaccines, with QS-21 being particularly noteworthy for its potent
immunostimulatory properties. QS-21, a saponin-based vaccine adjuvant
isolated from the bark of Quillaja saponaria, has garnered significant attention. However, its application as
vaccine adjuvant is limited due to its scarcity, complex chemical
synthesis, and inherent toxicity. This study aims to develop QS-21
analogues with simplified structures, enhanced immunogenicity, and
reduced toxicity. Our research findings indicate that the antibody
titers generated by the analogues VA05 and VA06 in conjunction with
the antigen are comparable to those induced by QS-21. With their lower
toxicity, VA05 and VA06 emerge as promising candidates for next-generation
adjuvant development, potentially surpassing QS-21 in both efficacy
and safety.